Literature DB >> 8067766

Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.

L E Bermudez1, L S Young, C B Inderlied.   

Abstract

Organisms of the Mycobacterium avium complex (MAC) cause disseminated disease in patients with AIDS, and evidence points to the gastrointestinal tract as the major route of infection. Since MAC can bind to and invade intestinal mucosal cells, we examined whether subinhibitory concentrations of antibiotics which have anti-MAC activity in vitro affect the interaction between MAC and HT-29 intestinal mucosal cells. MAC isolates were exposed to subinhibitory concentrations of rifabutin (MIC, 2.6 micrograms/ml), sparfloxacin (MIC, 8.4 micrograms/ml), or azithromycin (MIC, 32 micrograms/ml) for 30 to 120 min, washed, and incubated with HT-29 cell monolayers for 2 h at 4 degrees C. HT-29 cell monolayers were then washed to remove unbound bacteria and were subsequently lysed. The number of MAC isolates that bound to the HT-29 cells was determined by plating the cell lysate onto 7H10 agar. Preincubation of the MAC isolates with rifabutin at concentrations of 1 and 2 micrograms/ml reduced MAC binding to HT-29 cells by 80 to 90%, while MAC exposed to sparfloxacin at 1 and 7 micrograms/ml inhibited binding by 77 to 93%. Azithromycin at concentrations of 2, 10, and 30 micrograms/ml had no effect on MAC binding to HT-29 cells. Inhibition of MAC binding to the gastrointestinal mucosa may be one underlying mechanism for the prophylactic effects of rifabutin and quinolones.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8067766      PMCID: PMC188180          DOI: 10.1128/AAC.38.5.1200

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.

Authors:  C R Horsburgh
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  A single genetic locus encoded by Yersinia pseudotuberculosis permits invasion of cultured animal cells by Escherichia coli K-12.

Authors:  R R Isberg; S Falkow
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

3.  Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex.

Authors:  M A Bertram; C B Inderlied; S Yadegar; P Kolanoski; J K Yamada; L S Young
Journal:  J Infect Dis       Date:  1986-07       Impact factor: 5.226

4.  Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice.

Authors:  S K Furney; A D Roberts; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

5.  In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice.

Authors:  P R Gangadharam; V K Perumal; N R Podapati; L Kesavalu; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  In vitro interaction of Mycobacterium avium with intestinal epithelial cells.

Authors:  M E Mapother; J G Songer
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

7.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 8.  Mycobacterial infections in AIDS patients, with an emphasis on the Mycobacterium avium complex.

Authors:  L S Young; C B Inderlied; O G Berlin; M S Gottlieb
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

9.  Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods.

Authors:  C B Inderlied; L S Young; J K Yamada
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

10.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.

Authors:  B Dautzenberg; C Truffot; S Legris; M C Meyohas; H C Berlie; A Mercat; S Chevret; J Grosset
Journal:  Am Rev Respir Dis       Date:  1991-09
View more
  5 in total

Review 1.  Antimycobacterial susceptibility testing: present practices and future trends.

Authors:  C B Inderlied
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

Review 2.  Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.

Authors:  C A Peloquin
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

3.  Exposure to low oxygen tension and increased osmolarity enhance the ability of Mycobacterium avium to enter intestinal epithelial (HT-29) cells.

Authors:  L E Bermudez; M Petrofsky; J Goodman
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

4.  Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.

Authors:  L E Bermudez; C B Inderlied; P Kolonoski; M Petrofsky; L S Young
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 5.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.